Mar. 12 at 12:12 PM
$VSTM
"Verastem stock initiated
at Buy by BTIG with
$19 price target"
- March 11, 2026 at 05:05 PM
The firm cited the company’s two main pipeline programs as key drivers of value.
BTIG highlighted the launch of AVMAPKI FAKZYNJA
in LGSOC, which continues to exceed consensus expectations with potential for approximately
$1 billion in peak sales based on conservative market penetration assumptions.
The second program is KRASG12D inhibitor VS-7375, with additional data updates expected from the U.S. Phase 1/2 study this year and next.
BTIG said the upcoming data updates should increase conviction around the drug’s potential best-in-class profile in a competitive space.
The firm also noted data with six months of follow-up from all patients in the expansion cohort of the RAMP 205 study of avutometinib and defactinib in first-line metastatic pancreatic cancer as a high upside potential opportunity.
https://www.investing.com/news/analyst-ratings/verastem-stock-initiated-at-buy-by-btig-with-19-price-target-93CH-4555657
